T-cell receptor recognizing Dermatophagoides farinae peptide-MHC complexes (TCR-Der f-MHC)

The T-cell receptor (TCR) recognizing Dermatophagoides farinae peptide-MHC complexes is a critical mediator in the pathogenesis of house dust mite (HDM) allergy (Source: PubMed, PMID: 31201354). This receptor, primarily found on CD4+ T-lymphocytes, binds to specific allergenic peptides, such as Der f 1 or Der f 2, when they are presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (Source: UniProt). In sensitized individuals, this interaction triggers a Th2-biased immune response characterized by the secretion of pro-inflammatory cytokines like IL-4, IL-5, and IL-13 (Source: World Allergy Organization). These cytokines drive the production of allergen-specific IgE and the recruitment of eosinophils, leading to clinical symptoms of asthma, allergic rhinitis, and atopic dermatitis (Source: PubMed, PMID: 28434687). Therapeutic strategies targeting this TCR interaction include allergen-specific immunotherapy (AIT), such as Odactra, which aims to induce peripheral T-cell tolerance or shift the immune response toward a protective Th1 or regulatory T-cell (Treg) phenotype (Source: FDA). Drugs like Odactra utilize standardized allergen extracts to modulate this T-cell activity over time, reducing the allergic inflammatory cascade. Understanding the specificity of these TCRs is essential for developing precision vaccines and diagnostic tools for HDM-related allergic diseases. Research into TCR repertoires has shown that specific V-beta gene usage may be associated with the recognition of major Der f allergens, providing a basis for targeted molecular therapies.

Other names

House dust mite-specific T-cell receptorDer f-specific TCRHDM-specific TCRDermatophagoides farinae-specific T-cell receptor

Modulation of T-cell response through allergen-specific immunotherapy, leading to immune tolerance, T-cell anergy, or a shift from Th2 to Th1/Treg profiles.